quetiapine: the legal and safety record

The 2010 resolution, stated precisely

On April 27, 2010, AstraZeneca agreed to pay $520 million to resolve allegations that, from 2001 to 2006, it promoted Seroquel for uses the FDA never approved — insomnia, aggression, agitation among them — and aimed that promotion at primary care physicians, pediatricians and geriatricians, prescribers who, in the government’s words, do not typically treat schizophrenia or bipolar disorder [1]. Three facts keep this page honest. It was civil-only — no criminal charge, no plea, unlike the Zyprexa and Paxil cases elsewhere in this series. A civil settlement resolves allegations without a determination of liability. And the DOJ itself described it as the largest civil-only off-label marketing settlement to that date — a superlative about the settlement class, not a finding of guilt.

Why it still matters: the sleep prescription

The reason this sixteen-year-old case earns a page is continuity: low-dose quetiapine for insomnia — the marquee use in the allegations — remains one of the most common off-label psychiatric prescriptions in America. Quetiapine filled 8.7 million US prescriptions in 2024 [3]; public data cannot say what share is for sleep, and this page will not guess. What it can say: the use was never approved, the marketing that helped build it was the subject of a half-billion-dollar settlement, and the metabolic side-effect profile that makes an antipsychotic a heavy tool for insomnia is on our quetiapine page with the label quoted verbatim.

What is not in the record

• No criminal plea, no admission. Writing “found guilty” about this case is wrong in a checkable way [1].
• No adjudicated injury finding. The metabolic personal-injury claims settled confidentially years earlier; no court decided causation.
• No Class I recall — twelve records, all Class II/III [2].

Common questions

What did AstraZeneca pay $520 million for?

To resolve civil allegations, announced April 27, 2010, that between 2001 and 2006 it promoted Seroquel for uses the FDA never approved — insomnia, aggression, agitation and others — and marketed it to primary care physicians, pediatricians and geriatricians, prescribers who do not typically treat schizophrenia or bipolar disorder. There was no criminal charge, no plea, and no determination of liability: a civil settlement resolves allegations, and precision about that is the difference between reporting and overclaiming.

Is quetiapine approved for insomnia?

No. It is approved for schizophrenia and bipolar indications and as an adjunct in major depression. Low-dose quetiapine for sleep is off-label — legal to prescribe, heavily prescribed, and the exact use the 2010 allegations said was being promoted. The evidence question for a sleep prescription is therefore the one to ask: what trials support this dose for this use, against alternatives with far lighter metabolic baggage?

Was anyone found liable for Seroquel injuries?

The federal resolution was about marketing conduct, not injuries, and adjudicated no harm to any patient. Separate personal-injury litigation over diabetes and metabolic effects was largely resolved in confidential settlements years earlier — settled-confidentially, decided by no court.

Has quetiapine had serious recalls?

No Class I recall — FDA’s most serious category — appears in the openFDA enforcement database. Twelve records exist, eight Class II and four Class III, for manufacturing and quality issues rather than anything about the molecule.

Should I stop taking quetiapine because of this history?

No — not on your own, and for an antipsychotic the stakes of abrupt stopping are high. What the record sharpens is a question, not a decision: if the prescription is low-dose for sleep, ask what the evidence for that use is and whether weight, glucose and lipids are being monitored. If it is for schizophrenia or bipolar disorder, this page changes nothing about a treatment that has approval-grade evidence behind it.

Sources

Last verified 2026-09-01. Corrections change this date.